tumor lysis syndrome (tls) following intrathecal chemotherapy in a child with acute myelogenous leukemia (aml)
Clicks: 196
ID: 177060
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
6.6
/100
22 views
22 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by systemic chemotherapy, however, there have been case reports of TLS following intrathecal (IT) chemotherapy, all in patients with acute lymphoblastic leukemia (ALL)/lymphoma. Here, we report the first case of a patient with acute myelogenous leukemia (AML) who developed TLS following a single dose of IT cytosine arabinoside (Ara-C).
| Reference Key |
md2017leukemiatumor
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Chana L. Glasser, MD |
| Journal | urology annals |
| Year | 2017 |
| DOI |
10.1016/j.lrr.2017.10.002
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.